Table 2 MADRS scores and inflammatory biomarker concentrations at visits 1–7 (Mean ± SD)

From: Treatment of bipolar depression with minocycline and/or aspirin: an adaptive, 2×2 double-blind, randomized, placebo-controlled, phase IIA clinical trial

Outcome/visit Group N MADRS T; p-value (vs. P + P) CRP (mg/L) IL-6 (pg/mL) 11-D-TXB2 (pg/mL)
V1 M + A 31 28.0 ± 5.7 1.03; 0.308 8.2 ± 12.9 1.0 ± 0.7 2665 ± 2834
  M + P 19 27.2 ± 5.2 0.87; 0.386 4.3 ± 5.5 0.9 ± 0.5 2730 ± 2449
  A + P 19 25.9 ± 6.5 1.84; 0.069 4.5 ± 4.9 1.1 ± 0.7 4765 ± 3704
  P + P 30 29.2 ± 6.2   4.4 ± 5.3 0.9 ± 0.5 5038 ± 4626
V2 M + A 30 21.5 ± 7.1 1.92; 0.058
  M + P 18 21.4 ± 8.3 1.34; 0.185
  A + P 19 21.6 ± 7.2 1.44; 0.154
  P + P 27 25.0 ± 7.4  
V3 M + A 27 20.1 ± 6.8 1.34; 0.183
  M + P 17 19.8 ± 9.5 1.07; 0.288
  A + P 19 17.6 ± 7.3 2.08; 0.040*
  P + P 27 23.0 ± 9.7  
V4 M + A 27 17.8 ± 8.1 1.63; 0.108
  M + P 16 16.9 ± 8.5 0.54; 0.589
  A + P 18 15.9 ± 6.0 1.56; 0.122
  P + P 27 20.3 ± 9.2  
V5 M + A 27 15.9 ± 9.1 1.02; 0.311
  M + P 16 17.7 ± 9.0 0.11; 0.912
  A + P 16 15.2 ± 9.3 1.01; 0.318
  P + P 26 18.4 ± 8.5  
V6 M + A 24 15.5 ± 9.1 0.75; 0.455
  M + P 16 16.7 ± 7.6 0.12; 0.908
  A + P 14 13.7 ± 9.3 1.16; 0.251
  P + P 25 17.6 ± 9.3  
V7 M + A 22 14.5 ± 8.9 0.50; 0.619 10.3 ± 20.4 1.0 ± 0.5 1867 ± 2238
  M + P 15 15.5 ± 8.0 0.09; 0.928 2.2 ± 2.2 0.8 ± 0.3 3323 ± 3107
  A + P 14 12.3 ± 8.4 1.12; 0.267 3.9 ± 4.4 0.9 ± 0.5 963 ± 724
  P + P 24 16.0 ± 9.6   5.0 ± 5.2 1.0 ± 0.7 4565 ± 3498
  1. MADRS Montgomery–Äsberg Depression Rating Scale, CRP c-reactive protein, IL-6 interleukin-6, 11-D-TXB 2 Thromboxane B2
  2. *P < 0.05, uncorrected: ANOVA analysis controlling for sex, age, and BMI